A Study About The Anti-inflammatory Effect Of Ticagrelor In Unstable Angina Combined With Type 2 Diabetes Patients

Objective By detecting the serum concentration of s CD40 L,IL-6, hs CRP and peripheral blood CEC in UA combined with T2 DM patients to research for the anti-inflammatory effect and protecting vascular endothelial function of ticagrelor.Method According to inclusion and exclusion criteria, select 70 cases of patients with UA combined with T2 DM,randomly divided into group A(ticagrelor plus aspirin) and group B(clopidogrel plus aspirin), 35 cases in each group, and 20 cases patients without CAD or diabetes as control group in international medical center of Tianjin First Central Hospital. Group A patients given ticagrelor loading dose of 180 mg, and then ticagrelor 90 mg bid plus aspirin 100 mg QN to maintain; Group B patients given clopidogrel loading dose of 300 mg, and then clopidogrel 75 mg qd plus aspirin 100 mg QN, to maintain; Other medications are conventional medicine in secondary prevention of coronary heart disease(statin, low molecular heparin, B receptor blockers and ACEI, there were no statistically significant difference of nitrate).Group C of 20 cases of healthy controls, without any treatment. Collecting their clinical datas, which include related medical history such as hypertension, hyperlipemia, smoking history and some biochemical criterions, detecting the serum concentration of s CD40 L and IL-6 by enzyme linked immunosorbent assay;detecting the serum concentration of hs- CRP immunized with latex enhanced turbidimetric method,measurement peripheral blood CEC by flow cytometry, finally use statistical methods to analyze each inflammatory factor and the change of peripheral blood CEC.Result 1.Baseline data: There is no statistical difference among three groups(P>0.05);2. the serum concentration of hsCRP, IL-6,CD40 L peripheral blood CEC in Group A and group B significantly increased compared with group C before taking the medicine. There were no statistical significance difference in Group A and group B.3. the serum concentration of hs CRP in Group A and group B significantly decreased than before treatment and group A was lower than group B after 1 month of treatment.4.the serum concentration of IL-6 in Group A and group B significantly decreased than before treatment and group A was lower than group B after 1 month of treatment.5. the serum concentration of s CD40 L were no statistical significance difference in Group A and group B before treatment and after 1 month of treatment. There were no statistical significance difference between Group A and group B after 1 month of treatment.6. the levels of peripheral blood CEC in Group A was slightly decreased after 1 month of treatment. the peripheral blood levels of CEC in Group B has no obvious changes after 1 month of treatment.Conclusion Ticagrelor can reduce serum concentration of IL-6, hs CRP and peripheral blood CEC of the patients with unstable angina with type 2 diabetes mellitus. Ticagrelor had a stronger anti-inflammation and protecting endothelial function Compared with clopidogrel.